newsare.net
The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions andWhen cost stops being the barrier: The new chapter of Ozempic injection in India
The upcoming patent expiry for Ozempic in India is set to dramatically lower the cost of semaglutide, making this once-premium diabetes and weight-loss drug accessible to more patients. This shift could reshape the market, prompting earlier prescriptions and potentially altering societal views on weight management and body acceptance. Read more











